Holen Sie sich die Stockscreener-App
6.30
4.48%
0.27
Vorhandelsmarkt:
5.72
-0.58
-9.21%
Schlusskurs vom Vortag:
$6.03
Offen:
$5.96
24-Stunden-Volumen:
106.53K
Relative Volume:
0.46
Marktkapitalisierung:
$70.95M
Einnahmen:
$1.54M
Nettoeinkommen (Verlust:
$-38.70M
KGV:
-1.349
EPS:
-4.67
Netto-Cashflow:
$-36.86M
1W Leistung:
+8.62%
1M Leistung:
+9.57%
6M Leistung:
-64.35%
1J Leistung:
-83.94%
1-Tages-Spanne:
$5.90
$6.355
1-Wochen-Bereich:
$5.73
$6.355
52-Wochen-Spanne:
$4.64
$61.90
Corbus Pharmaceuticals Holdings Inc Stock (CRBP) Company Profile
Firmenname
Corbus Pharmaceuticals Holdings Inc
Sektor
Branche
Telefon
617-963-0103
Adresse
500 RIVER RIDGE DRIVE, NORWOOD, MA
Vergleichen Sie CRBP mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CRBP
Corbus Pharmaceuticals Holdings Inc
|
6.30 | 70.95M | 1.54M | -38.70M | -36.86M | -4.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.52 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.49 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
595.70 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
232.75 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
229.22 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Corbus Pharmaceuticals Holdings Inc Stock (CRBP) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-28 | Eingeleitet | William Blair | Outperform |
| 2024-12-02 | Eingeleitet | Piper Sandler | Overweight |
| 2024-07-30 | Eingeleitet | Wedbush | Outperform |
| 2024-07-22 | Fortgesetzt | H.C. Wainwright | Buy |
| 2024-06-26 | Eingeleitet | B. Riley Securities | Buy |
| 2024-06-03 | Bestätigt | Oppenheimer | Outperform |
| 2024-05-13 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2024-03-06 | Hochstufung | Jefferies | Hold → Buy |
| 2020-09-08 | Herabstufung | BTIG Research | Buy → Neutral |
| 2020-09-08 | Herabstufung | Jefferies | Buy → Hold |
| 2020-09-08 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-09-08 | Herabstufung | ROTH Capital | Buy → Neutral |
| 2020-07-07 | Eingeleitet | ROTH Capital | Buy |
| 2020-06-17 | Eingeleitet | BTIG Research | Buy |
| 2020-03-26 | Eingeleitet | Nomura | Buy |
| 2019-04-05 | Eingeleitet | Jefferies | Buy |
| 2019-03-20 | Eingeleitet | Oppenheimer | Outperform |
| 2019-01-11 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2018-12-26 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-12-07 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2018-10-24 | Eingeleitet | B. Riley FBR | Buy |
| 2018-01-19 | Eingeleitet | Raymond James | Outperform |
| 2017-12-14 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2017-11-08 | Bestätigt | Noble Financial | Buy |
| 2017-09-29 | Fortgesetzt | Noble Financial | Buy |
| 2017-03-30 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2016-11-15 | Bestätigt | JMP Securities | Mkt Outperform |
| 2016-11-11 | Bestätigt | Noble Financial | Buy |
Alle ansehen
Corbus Pharmaceuticals Holdings Inc Aktie (CRBP) Neueste Nachrichten
(CRBP) Trading Report - news.stocktradersdaily.com
We Think Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) Can Afford To Drive Business Growth - Yahoo Finance
Wall Street Analysts See a 764.18% Upside in Corbus Pharmaceuticals (CRBP): Can the Stock Really Move This High? - Yahoo Finance
Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors on strong trading day - MarketWatch
CRBP stock touches 52-week low at $4.64 amid sharp annual decline - Investing.com
CRBP stock touches 52-week low at $4.64 amid sharp annual decline By Investing.com - Investing.com South Africa
Where are the Opportunities in (CRBP) - news.stocktradersdaily.com
Corbus Pharmaceuticals Holdings Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Corbus Pharmaceuticals Holdings Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Analysts Set Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Target Price at $59.13 - Defense World
Corbus Pharmaceuticals Holdings Inc. stock underperforms Monday when compared to competitors - MarketWatch
Charles Schwab Investment Management Inc. Purchases 4,239 Shares of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) - Defense World
Corbus Pharmaceuticals Holdings Inc. stock underperforms Friday when compared to competitors - MarketWatch
CRBP Stock Plummets to 52-Week Low of $5.65 Amid Market Turbulence By Investing.com - Investing.com South Africa
Corbus begins Phase 1 trial for new obesity treatment CRB-913 By Investing.com - Investing.com South Africa
CRBP Stock Plummets to 52-Week Low of $5.65 Amid Market Turbulence - Investing.com
Corbus Pharmaceuticals Announces First Patient Dosed in Phase 1 Clinical Study of Next-Generation CB1 Inverse Agonist CRB-913 for the Treatment of Obesity - Quantisnow
Corbus begins Phase 1 trial for new obesity treatment CRB-913 - Investing.com
Corbus Pharmaceuticals Announces First Patient Dosed in - GlobeNewswire
Next-Gen Obesity Drug Shows 50x Better Safety Profile Than Previous Treatments as Clinical Trials Begin - Stock Titan
Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors despite losses on the day - MarketWatch
Corbus Pharmaceuticals Holdings Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
(CRBP) Technical Pivots with Risk Controls - news.stocktradersdaily.com
Corbus Pharmaceuticals to reduce board size post-annual meeting By Investing.com - Investing.com Canada
Corbus Pharmaceuticals Holdings Inc. filed SEC Form 8-K: Leadership Update - Quantisnow
Corbus Pharmaceuticals to reduce board size post-annual meeting - Investing.com
Corbus Pharmaceuticals Announces Board Member Departure - TipRanks
CRBP stock touches 52-week low at $5.9 amid steep annual decline - Investing.com Australia
CRBP stock touches 52-week low at $5.9 amid steep annual decline By Investing.com - Investing.com South Africa
After Plunging -22.69% in 4 Weeks, Here's Why the Trend Might Reverse for Corbus Pharmaceuticals (CRBP) - Yahoo Finance
After Plunging -22.9% in 4 Weeks, Here's Why the Trend Might Reverse for Corbus Pharmaceuticals (CRBP) - Yahoo Finance
Corbus Pharmaceuticals appoints new COO By Investing.com - Investing.com Australia
Corbus Pharmaceuticals Appoints Ian Hodgson as COO - TipRanks
Corbus Pharmaceuticals appoints new COO - Investing.com
B. Riley Lifts Earnings Estimates for Corbus Pharmaceuticals - Defense World
HC Wainwright Issues Positive Estimate for CRBP Earnings - Defense World
Corbus Pharmaceuticals (NASDAQ:CRBP) Price Target Cut to $53.00 by Analysts at Jefferies Financial Group - MarketBeat
Lifesci Capital Has Optimistic Outlook of CRBP Q1 Earnings - Defense World
What is B. Riley’s Forecast for CRBP Q1 Earnings? - Defense World
Wedbush Reaffirms Outperform Rating for Corbus Pharmaceuticals (NASDAQ:CRBP) - Defense World
Corbus Pharmaceuticals (NASDAQ:CRBP) Earns “Buy” Rating from HC Wainwright - Defense World
Finanzdaten der Corbus Pharmaceuticals Holdings Inc-Aktie (CRBP)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.15%
4.32%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):